What we're reading, April 7, 2016: hospitals will help Louisiana pay for Medicaid expansion; Pfizer considers splitting the company after deal with Allergan falls through; and Pfizer gets 300 lawsuits dismissed.
Under new legislation being finalized in Louisiana, hospitals in the state will be charged a fee to help the state pay for Medicaid expansion. The Louisiana Hospital Association was in favor of expanding the program and supported the efforts to enact a fee to help pay, reported The Times-Picayune. The hospitals will be paying up to 40% of the cost of expansion and the fee will be reassessed each year.
After new rules aimed at the Pfizer-Allergan merger that used a controversial tax inversion were revealed earlier this week, the deal was called off. Now, Pfizer is considering an old plan first considered 5 years ago: splitting the company up, according to STAT. The split would create 2 entities: one that focused on the established business and produced older drugs, and one that focused on innovative business and produced newer and forthcoming products.
Just days after receiving the bad news from the Treasury Department, Pfizer got some good new regarding some lawsuits it was facing. A judge in Philadelphia dismissed more than 300 lawsuits alleging that Zoloft caused birth defects in children born to women who took the antidepressant while they were pregnant, reported Reuters. The judge ruled that the plaintiffs had not produced enough evidence showing a plausible link between the drug and the birth defects.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment
April 21st 2025An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.
Read More